title: [Brain in the core of metabolic regulations: disorders in schizophrenic patients treated with atypical antipsychotics].
abstract: Schizophrenia is associated with an increased risk of metabolic disorders such as diabetes, dyslipidaemia and the metabolic syndrome. The prevalence of type 2 diabetes in schizophrenic patients is at least twice that of the general population. Around 40 percent of patients meet criteria for the metabolic syndrome. Recently there is a growing concern on the metabolic side effects of treatment with second generation antipsychotics. According to various studies, including a prospective study performed in Flanders, treatment with clozapine and olanzapine has the highest metabolic risk, followed by quetiapine and risperidone. Amisulpride, ziprasidone and aripiprazole appear to have a low metabolic risk. Appropriate care, taking into account the possible improvement of the metabolic risks factors, is important to reduce morbidity and mortality in schizophrenic patients treated with antipsychotic medications.
authors.affiliation: Département des Sciences de la Santé publique, CHU Sart Tilman, Liège, Belgique.
authors.forename: L
authors.initials: L
authors.lastname: Hanssens
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
authors.forename: R
authors.initials: R
authors.lastname: van Winkel
authors.forename: D
authors.initials: D
authors.lastname: Van Eyck
authors.forename: J Y
authors.initials: JY
authors.lastname: Reginster
authors.forename: M
authors.initials: M
authors.lastname: De Hert
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D014150:Antipsychotic Agents